BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

The lackluster U.S. biosimilars market has led to calls for a new regulatory paradigm that could slash the cost of development. Biosimilars developers and critics of the sector agree on one thing: as it has...
BC Extra | Feb 11, 2019
Company News

Agios' Schenkein joins GV

Less than two weeks after stepping down as CEO of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), David Schenkein has joined GV as general partner. Schenkein, who will remain executive chairman of Agios, will co-lead the firm’s life...
BC Innovations | Jan 11, 2019
Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
BC Extra | Sep 11, 2018
Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
BioCentury | Aug 24, 2018
Finance

Navigating the Hot Topics landscape

Investors are making aggressive bets on the ability of early stage companies to deliver on the next generation of therapeutics and technologies. But advances in biology and novel technologies come with challenges ranging from unknown...
BC Extra | Jul 2, 2018
Company News

Dunsire to become Lundbeck CEO

Neurology company H. Lundbeck A/S (CSE:LUN) hired Deborah Dunsire as president and CEO, effective Sept. 1. Dunsire will fill a position that became vacant when Kåre Schultz resigned in September 2017. CFO Anders Götzsche has...
Items per page:
1 - 10 of 1859
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

The lackluster U.S. biosimilars market has led to calls for a new regulatory paradigm that could slash the cost of development. Biosimilars developers and critics of the sector agree on one thing: as it has...
BC Extra | Feb 11, 2019
Company News

Agios' Schenkein joins GV

Less than two weeks after stepping down as CEO of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), David Schenkein has joined GV as general partner. Schenkein, who will remain executive chairman of Agios, will co-lead the firm’s life...
BC Innovations | Jan 11, 2019
Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
BC Extra | Sep 11, 2018
Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
BioCentury | Aug 24, 2018
Finance

Navigating the Hot Topics landscape

Investors are making aggressive bets on the ability of early stage companies to deliver on the next generation of therapeutics and technologies. But advances in biology and novel technologies come with challenges ranging from unknown...
BC Extra | Jul 2, 2018
Company News

Dunsire to become Lundbeck CEO

Neurology company H. Lundbeck A/S (CSE:LUN) hired Deborah Dunsire as president and CEO, effective Sept. 1. Dunsire will fill a position that became vacant when Kåre Schultz resigned in September 2017. CFO Anders Götzsche has...
Items per page:
1 - 10 of 1859